Eris Lifesciences Projects Strong Growth: FY26 Revenue Forecast at ₹2,900-3,050 Crore May 19, 2025
Eris Lifesciences has released its financial projections for FY26 in an investor presentation. The company aims for revenue between ₹2,900-3,050 crore and EBITDA of ₹1,070-1,130 crore. It expects to maintain a 37% EBITDA margin, indicating strong operational efficiency. These projections reflect the company's confidence in its growth strategies and align with broader expansion trends in the Indian pharmaceutical sector.
Eris Lifesciences: Q4 Profit Surges 31%, EBITDA Margin Expands to 36% May 19, 2025
Eris Lifesciences Reshuffles Holdings: Transfers Two Subsidiaries to Eris Therapeutics for Rs. 862 Crore Mar 07, 2025
Eris Lifesciences Restructures Holdings: Sells Subsidiaries for Rs 861.9 Crore Amid Q3 Profit Decline Mar 06, 2025